论文部分内容阅读
目的:观察IEPP联合化疗方案治疗难治性恶性淋巴瘤的疗效。方法:采用IFO 1.5g/~2,静滴、d1～5;Mesna0.4g,静注,于IFO静滴后0、4、8小时各一次,d1～5;Vp—16 100mg/m~2,静滴,d 1～5;DPP 20mg/m~2,静滴,d 1～5;PDN 70mg/m~2,口服,d 1～5。以上方案连用2～3周期。结果:全组13例,CR 2例,PR9例,总有效率84.61％。毒副反应主要是白细胞和血小板下降发生率分别达100％、46.1％,白细胞Ⅲ、Ⅳ度毒性为38.5％、23.1％。结论:IEPP方案治疗难治性恶性淋巴瘤疗效较为满意,虽有较明显的血液学毒性,但在小剂量C—CSF支持卜还是安全可行的。
Objective: To observe the efficacy of IEPP combined with chemotherapy in the treatment of refractory malignant lymphoma. Methods: IFO 1.5g / ~ 2, intravenous drip, d1 ~ 5; Mesna0.4g, intravenous injection, once every 0,4,8 hours IFO intravenous drip, d1 ~ 5; Vp-16 100mg / m ~ 2 , Intravenous drip, d 1 ~ 5; DPP 20mg / m ~ 2, intravenous drip, d 1 ~ 5; PDN 70mg / m ~ 2, oral, d 1 ~ The above program used in conjunction 2 to 3 cycles. Results: The whole group of 13 cases, CR 2 cases, PR 9 cases, the total effective rate 84.61%. Toxic and side effects are mainly white blood cells and thrombocytopenia were 100%, 46.1%, white blood cells Ⅲ, Ⅳ degree of toxicity was 38.5%, 23.1%. Conclusion: The IEPP regimen is satisfactory for the treatment of refractory malignant lymphoma. Although it has obvious hematologic toxicity, it is safe and feasible to use low dose C-CSF support.